← Eichor
Study identifier: NCT01665326 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

Condition: Pompe Disease  ·  Sponsor: Duke University

PhaseN/A
Planned participants400
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

This is a longitudinal natural history study of Infantile Pompe disease. The investigators will regularly collect and review medical information regarding the diagnosis of Pompe disease, response to enzyme replacement (ERT) using alglucosidase alfa (Lumizyme/Myozyme) and response to immunosuppressive therapy in cases at risk for developing or those who have developed high and sustained antibodies to ERT. To follow the long-term outcomes, we will collect medical records including but not limited to the diagnosis, clinical parameters, assessments for clinical monitoring, and laboratory values including antibody testing results.

This description comes directly from the study's public registry record.

Talk to the study team

Ankit K Desai, MBBS  ·  919-613-6310  ·  ankit.desai@duke.edu

Eleanor Rodriguez-Rassi, MPH  ·  919-613-1219  ·  eleanor.rodriguezrassi@duke.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Duke University Medical CenterDurham, North Carolina, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT01665326